SOUTH SAN FRANCISCO, Calif., Jan. 9, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical development company with a focus on innovative therapies for patients with debilitating diseases, today announced that Isaac Ciechanover, M.D., the company's Chief Executive Officer, will present at the 2015 J.P. Morgan Healthcare Conference on Thursday, January 15, 2015 at 12:00 pm PT in San Francisco.
The live audio webcast of the company presentation will be accessible from the company's investor relations website at http://investors.atarabio.com/events.cfm. Please connect to the website prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast. An archive of the webcast will be available for at least 30 days following the presentation.
About Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. is a biopharmaceutical development company focusing on innovative therapies for patients with debilitating diseases. The company's lead programs are focused on myostatin and activin, members of the TGF- β family of proteins that have demonstrated the potential to have therapeutic benefit in a number of clinical indications. Atara is also collaborating with Memorial Sloan Kettering Cancer Center (MSK) in the development of three T cell product candidates: Epstein-Barr virus (EBV)-targeted cytotoxic T lymphocytes (CTLs), cytomegalovirus (CMV)-targeted CTLs, and Wilms Tumor 1 (WT1)-targeted CTLs. Each product candidate is designed to address the underlying mechanisms of disease to treat conditions which have few therapeutic options today.
CONTACT: Tina Gullotta firstname.lastname@example.org 650-741-1613Source:Atara Biotherapeutics